Epiminder Limited

Epiminder Limited

EPI.AX
Epiminder LimitedAU flagAustralian Securities Exchange
0.26
AUD
+0.00
- -
56.33MMarket Cap
2023 Y
2024 Y
2025 Y
2026 Y
Revenue per Share
- -
- -
- -
- -
Basic EPS, GAAP
-0.12
-0.13
-0.2
-0.28
Free Cash Flow per Basic Share
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
Book Value per Share
- -
- -
0.61
0.38
Tangible Book Value per Share
- -
- -
0.54
0.32
Basic Weighted Avg Shares
175
175
175
151
Sales/Revenue/Turnover
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
Net Income, GAAP
-21
-22
-35
-43
Effective Tax Rate (%)
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
Working Capital
- -
- -
94
70
LT Debt
- -
- -
- -
- -
Total Equity
- -
- -
107
82
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-64.28
-45.21

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-23.94%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
23.82%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.13
2025
- -
- -
- -
- -
-0.2
2026
- -
- -
- -
- -
-0.28

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Rohan J. Hoare
Sector
Healthcare
Industry
Medical - Devices
Address
West Podium, Mezzanine 2 Melbourne VIC Australia 3000
IPO Date
Nov 30, 2025
Business
Epiminder Limited engages in the development and manufacture of monitoring device to improve treatment of patients suffering with epileptic seizures and related conditions. The company offers Minder system, an electroencephalographic (EEG) recording and transmitting device implanted under the scalp. Its Minder system comprises Minder Implant, a sub scalp electrode with multiple recording points which enables capture of EEG continuously for months or years; Minder Wearable, which receives and stores EEG recordings wirelessly transmitted from the Minder implant to the Minder app; Minder App that collects and transmits EEG data from the Minder implant via Bluetooth and uploads to the Minder Cloud for processing; and Minder Cloud, a secure, online portal which allows healthcare professionals to download patient data. The company was incorporated in 2017 and is based in Melbourne, Australia.